Barclays analyst Gena Wang raised the firm’s price target on Bluebird Bio (BLUE) to $40 from $2 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect ...
Barclays analyst Gena Wang maintained a Buy rating on Bluebird Bio (BLUE – Research Report) yesterday and set a price target of $40.00. Discover the latest stocks recommended by top Wall Street ...
Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.